Table 1.

Baseline demographic and clinical characteristics

Nivolumab N = 34
Sex
 Male29 (85)
 Female5 (15)
 Age, years, median (range)68.0 (43–78)
 Body mass index, kg/m2, median (range)22.1 (15.8–29.0)
Number of prior treatment(s)
 124 (71)
 210 (29)
Performance status
 013 (38)
 121 (62)
Previous systemic therapy
First line
 Pemetrexed + cisplatin/carboplatin31 (91)
 Pemetrexed + cisplatin + BBI6082 (6)
 Pemetrexed + cisplatin + bevacizumab1 (3)
Second line
 Gemcitabine3 (9)
 Pemetrexed + cisplatin/carboplatin3 (9)
 Pemetrexed2 (6)
 Other2 (6)
PD-L1 status
 ≥1%20 (59)
 <1%12 (35)
 NE2 (6)
Histological subtype
 Epithelioid27 (79)
 Biphasic4 (12)
 Sarcomatoid3 (9)
  • NOTE: Data are n (%), unless otherwise stated.